Vir Biotechnology (VIR) to Release Earnings on Thursday

Vir Biotechnology (NASDAQ:VIR - Get Free Report) will be announcing its earnings results after the market closes on Thursday, October 31st. Analysts expect the company to announce earnings of ($0.96) per share for the quarter. Parties interested in listening to the company's conference call can do so using this link.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported ($1.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.13). The business had revenue of $3.08 million during the quarter, compared to analysts' expectations of $7.53 million. Vir Biotechnology had a negative net margin of 612.40% and a negative return on equity of 30.93%. The company's revenue for the quarter was down 19.0% compared to the same quarter last year. During the same period last year, the business posted ($1.45) earnings per share. On average, analysts expect Vir Biotechnology to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Vir Biotechnology Stock Down 2.3 %

Vir Biotechnology stock traded down $0.17 during mid-day trading on Thursday, reaching $7.35. 732,608 shares of the company's stock traded hands, compared to its average volume of 987,860. Vir Biotechnology has a 12-month low of $7.12 and a 12-month high of $13.09. The company has a market cap of $1.00 billion, a price-to-earnings ratio of -2.05 and a beta of 0.46. The stock has a 50 day moving average of $7.88 and a two-hundred day moving average of $8.93.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on VIR shares. HC Wainwright restated a "buy" rating and set a $110.00 target price on shares of Vir Biotechnology in a research report on Tuesday, August 20th. Barclays upped their price objective on Vir Biotechnology from $27.00 to $28.00 and gave the company an "overweight" rating in a research report on Friday, August 2nd. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $36.80.

Insider Buying and Selling

In other Vir Biotechnology news, Director Janet Napolitano sold 12,190 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $7.80, for a total value of $95,082.00. Following the sale, the director now owns 11,616 shares in the company, valued at $90,604.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 15.60% of the stock is owned by corporate insiders.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).